Free Access
Med Sci (Paris)
Volume 30, Number 6-7, Juin–Juillet 2014
Page(s) 608 - 610
Section Nouvelles
Published online 11 July 2014
  1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the american heart association. Circulation 2014 ; 129 : e28–e292. [CrossRef] [PubMed] [Google Scholar]
  2. Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke 2014 ; 45 : 315–353. [CrossRef] [PubMed] [Google Scholar]
  3. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976 ; 7 : 135–142. [CrossRef] [PubMed] [Google Scholar]
  4. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995 ; 333 : 1581–1587. [CrossRef] [PubMed] [Google Scholar]
  5. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013 ; 44 : 870–947. [CrossRef] [PubMed] [Google Scholar]
  6. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008 ; 372 : 1303–1309. [CrossRef] [PubMed] [Google Scholar]
  7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 ; 359 : 1317–1329. [CrossRef] [PubMed] [Google Scholar]
  8. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007 ; 369 : 275–282. [CrossRef] [PubMed] [Google Scholar]
  9. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013 ; 368 : 893–903. [CrossRef] [PubMed] [Google Scholar]
  10. Galaup A, Gomez E, Souktani R, et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 2012 ; 125 : 140–149. [CrossRef] [PubMed] [Google Scholar]
  11. Bouleti C, Mathivet T, Coqueran B, et al. Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. Eur Heart J 2013 ; 34 : 3657–3668. [CrossRef] [PubMed] [Google Scholar]
  12. Le Jan S, Amy C, Cazes A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003 ; 162 : 1521–1528. [CrossRef] [PubMed] [Google Scholar]
  13. Galaup A, Cazes A, Le Jan S, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006 ; 103 : 18721–18726. [CrossRef] [Google Scholar]
  14. Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008 ; 133 : 66–77. [CrossRef] [PubMed] [Google Scholar]
  15. Cazes A, Galaup A, Chomel C, et al. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res 2006 ; 99 : 1207–1215. [CrossRef] [PubMed] [Google Scholar]
  16. Chomel C, Cazes A, Faye C, et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. Faseb J 2009 ; 23 : 940–949. [CrossRef] [PubMed] [Google Scholar]
  17. Zhu P, Goh YY, Chin HF, et al. Angiopoietin-like 4: a decade of research. Bioscience reports 2012 ; 32 : 211–219. [CrossRef] [PubMed] [Google Scholar]
  18. Galaup A, Germain S. Protèger l’intégrité du réseau vasculaire coronaire. Med Sci (Paris) 2012 ; 28 : 133–135. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  19. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci USA 2006 ; 103 : 17450–17455. [CrossRef] [Google Scholar]
  20. Lafferty MJ, Bradford KC, Erie DA, Neher SB. Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation. J Biol Chem 2013 ; 288 : 28524–28534. [CrossRef] [PubMed] [Google Scholar]
  21. Eltzschig HK, Eckle T. Ischemia and reperfusion: from mechanism to translation. Nat Med 2011 ; 17 : 1391–1401. [CrossRef] [PubMed] [Google Scholar]
  22. Leys D, Cordonnier C. Traitements des accidents vasculaires cérébraux en phase aiguë et prévention secondaire. Med Sci (Paris) 2009 ; 25 : 733–738. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  23. Bordet R, Ouk T, Onténiente B, et al. Ischémie cérébrale. Les pistes thérapeutiques de demain. Med Sci (Paris) 2009 ; 25 : 847–854. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Macé C, Clément LC. Implication d’Angptl4 dans le syndrome néphrotique : une protéine à deux visages. Med Sci (Paris) 2014 ; 30 : 605–607. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.